Clinical Trials Browser

Phase 2 × INDUSTRY × sargramostim × Clear all

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Phase 2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Phase 2 Completed

156 enrolled 11 charts

Melanoma

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

22 enrolled 8 charts

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05771584 2024-07-10

Conerstone3

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05163223 2024-06-17

Cornerstone001

Phase 2 Terminated

Breast Neoplasms

NCT04713371 2024-05-09

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT02297698 2023-12-12

HER3+

Phase 2 Completed

100 enrolled 11 charts

Breast Neoplasms

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT05794659 2023-07-20

Cornerstone4

Phase 2 Not yet recruiting

Advanced Ovarian Cancer

NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Phase 2 Terminated

120 enrolled 12 charts

Ovarian Neoplasms

NCT02873819 2022-03-08

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT01570036 2020-12-02

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Phase 2 Completed

275 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00458601 2018-01-16

ACT III

Phase 2 Completed

Glioma

NCT01909752 2017-07-06

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02520102 2017-04-20

Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00308087 2013-12-27

PREMIER

Phase 2 Terminated

75 enrolled 12 charts

Lymphoma, Follicular

NCT00523159 2012-07-10

IMA901-202

Phase 2 Completed

Carcinoma, Renal Cell